RE: Synairgen and Soton Uni24 Mar 2020 10:54
founded by leading academics from the University of Southampton (Profs Holgate, Djukanovic and Davies). Synairgen’s most advanced programme is the development of inhaled interferon beta (SNG001) for the treatment of virus induced exacerbations of respiratory disease, currently in Phase 2 for COPD. Synairgen is also collaborating with Australian biotech Pharmaxis to develop small molecular weight inhibitors of LOXL2 for the treatment of IPF and other fibrotic conditions.